Partners hit as Reata ends PhIII BEACON trial with bardoxolone in CKD
This article was originally published in Scrip
Abbott investors sent the company's stock down for the second day in a row after its partner Reata Pharmaceuticals said on 18 October that the private firm had terminated the Phase III BEACON clinical trial evaluating its antioxidant inflammation modulator (AIM) bardoxolone methyl (RTA 402) in the treatment of patients with chronic kidney disease (CKD) and type 2 diabetes.
You may also be interested in...
Latest data support moving bardoxolone into Phase III for autosomal dominant polycystic kidney disease (ADPKD).
What's the best metaphor for the past two weeks of US biotechnology initial public offerings? That would be a sharp intake of air through the teeth – the sound you make when you see someone do something really painful.
Paige’s AI has obtained CE-IVD and UKCA marks, allowing the launch of a breakthrough product that can spot biomarkers from images.